What are Analysts report about Visa Inc.(NYSE:V): Editas Medicine, Inc.(NASDAQ:EDIT)

0
14
touch screen graph on tablet

Visa Inc. (V) will report its next earnings on Apr 24 AMC. The company reported the earnings of $1.3/Share in the last quarter where the estimated EPS by analysts was $1.25/share. The difference between the expected and actual EPS was $0.05/share, which represents an Earnings surprise of 4%.

Many analysts are providing their Estimated Earnings analysis for Visa Inc. and for the current quarter 35 analysts have projected that the stock could give an Average Earnings estimate of $1.24/share. These analysts have also projected a Low Estimate of $1.2/share and a High Estimate of $1.29/share.

In case of Revenue Estimates, 31 analysts have provided their consensus Average Revenue Estimates for Visa Inc. as 5.46 Billion. According to these analysts, the Low Revenue Estimate for Visa Inc. is 5.29 Billion and the High Revenue Estimate is 5.63 Billion. The company had Year Ago Sales of 5.07 Billion.

These analysts also forecasted Growth Estimates for the Current Quarter for V to be 11.7%. They are projecting Next Quarter growth of 11.67%. For the next 5 years, Visa Inc. is expecting Growth of 16% per annum, whereas in the past 5 years the growth was 15.4% per annum.

Some buy side analysts are also providing their Analysis on Visa Inc., where 6 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 2 said it’s a HOLD, and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

When it comes to the Analysis of a Stock, Price Target plays a vital role. Analysts reported that the Price Target for Visa Inc. might touch $196 high while the Average Price Target and Low price Target is $166.42 and $143 respectively.

Visa Inc. closed its last trading session at $157.49 with the gain of 0.68%. The Market Capitalization of the company stands at 348.34 Billion. The Company has 52-week high of $159.11 and 52-week low of $119.37. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 1.91% where SMA50 and SMA200 are 6.6% and 11.86% respectively. The Company Touched its 52-Week High on 04/03/19 and 52-Week Low on 04/25/18.

The Relative Volume of the company is 0.45 and Average Volume (3 months) is 8.65 million. The company’s P/E (price to earnings) ratio is 34.08 and Forward P/E ratio of 25.73.

The company shows its Return on Assets (ROA) value of 14.9%. The Return on Equity (ROE) value stands at 36.5%. While it’s Return on Investment (ROI) value is 20.6%.

While looking at the Stock’s Performance, Visa Inc. currently shows a Weekly Performance of 0.06%, where Monthly Performance is 4.5%, Quarterly performance is 14.56%, 6 Months performance is 11.75% and yearly performance percentage is 31.35%. Year to Date performance value (YTD perf) value is 20.18%. The Stock currently has a Weekly Volatility of 1.00% and Monthly Volatility of 1.28%.

Editas Medicine, Inc. (EDIT) will report its next earnings on Feb 28 AMC. The company reported the earnings of $-0.32/Share in the last quarter where the estimated EPS by analysts was $-0.66/share. The difference between the expected and actual EPS was $0.34/share, which represents an Earnings surprise of 51.5%.

Many analysts are providing their Estimated Earnings analysis for Editas Medicine, Inc. and for the current quarter 0 analysts have projected that the stock could give an Average Earnings estimate of $0/share. These analysts have also projected a Low Estimate of $0/share and a High Estimate of $0/share.

In case of Revenue Estimates, 5 analysts have provided their consensus Average Revenue Estimates for Editas Medicine, Inc. as 18.7 Million. According to these analysts, the Low Revenue Estimate for Editas Medicine, Inc. is 1.5 Million and the High Revenue Estimate is 32 Million. The company had Year Ago Sales of 3.67 Million.

These analysts also forecasted Growth Estimates for the Current Quarter for EDIT to be 4.5%. They are projecting Next Quarter growth of 12.2%. For the next 5 years, Editas Medicine, Inc. is expecting Growth of -13.19% per annum, whereas in the past 5 years the growth was -17.6% per annum.

Some buy side analysts are also providing their Analysis on Editas Medicine, Inc., where 0 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 1 said it’s a HOLD, and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

When it comes to the Analysis of a Stock, Price Target plays a vital role. Analysts reported that the Price Target for Editas Medicine, Inc. might touch $55 high while the Average Price Target and Low price Target is $41.14 and $30 respectively.

Editas Medicine, Inc. closed its last trading session at $26.67 with the gain of 3.75%. The Market Capitalization of the company stands at 1.32 Billion. The Company has 52-week high of $41.43 and 52-week low of $17.80. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 11.9% where SMA50 and SMA200 are 22.02% and -0.08% respectively. The Company Touched its 52-Week High on 06/21/18 and 52-Week Low on 12/24/18.

The Relative Volume of the company is 0.55 and Average Volume (3 months) is 998.85 million. The company’s P/E (price to earnings) ratio is 0 and Forward P/E ratio of 0.

The company shows its Return on Assets (ROA) value of -27.4%. The Return on Equity (ROE) value stands at -46.8%. While it’s Return on Investment (ROI) value is -42.3%.

While looking at the Stock’s Performance, Editas Medicine, Inc. currently shows a Weekly Performance of 3.44%, where Monthly Performance is 14.01%, Quarterly performance is 4.81%, 6 Months performance is -0.68% and yearly performance percentage is -18.98%. Year to Date performance value (YTD perf) value is 21.63%. The Stock currently has a Weekly Volatility of 4.08% and Monthly Volatility of 4.24%.

SHARE